PARP1 and acute myeloid leukemia: Figure 3 (upper panel) shows the characteristics of the patients whose MNCs were used in this study. Exposure of the isolated MNCs to [Bu+4HC], [Bu+Flu] or ABT199/venetoclax (lanes 2, 3, and 4, respectively) resulted in minimal cleavages of PARP1 and CASPASE 3 relative to the control cells (lane 1) but exposure to [Bu+4HC+ABT199] or [Bu+Flu+ABT199] (lanes 5 and 6) substantially increased the level of their cleavage product (Figure 3), consistent with what was seen in the three established AML cell lines (Figure 2A).